Biotech Values

[mcbio]

ImmunoCellular Therapeutics (OTC:IMUC) is developing a Phase II GBM candidate. The company has a market cap of USD 47m. Oncologists interviewed by this news service have noted that the drug has a better profile than Celldex’s competing agent, CDX- 110.

Would love to know what the assertion that IMUC's GBM drug has a better profile than CLDX's CDX-110 is based on. Also, CDX-110 is arguably not even CLDX's most important drug, even if it is furthest along. (I think most would say that distinction belongs to CDX-011, the breast cancer MAB with the SGEN ADC now in Phase 2b with top-line results to be reported at next year's ASCO.)